Furthermore, NSCLC tumors, tightly linked to laryngeal cancer by cellular origin and histology, have been reported to express another activator of the alternative NF-κB pathway, CD40 and its ligand, CD154, providing another possible molecular mechanism for alternative NF-κB activation [38]. This evidence concerns the gene CD40 and laryngeal carcinoma.